Oritavancin

Records for this ingredient, by country (identity only).

ATC J01XA05 · 6 markets · 9 records

Oritavancin 6 markets · 9 records Forms
Filters
MarketCA 2ES 2FR 2US 1GB 1EU 1

CA 2 records · 2 shown of 2 Source Health Canada Drug Product Databas · Data as of 2026-10-23

ES 2 records · 2 shown of 2 Source CIMA (AEMPS) · Data as of live

  • 400 mg per mL / per unit basis not statedinjectionTENKASI
  • 1,200 mg per mL / per unit basis not statedinjectionTENKASI

FR 2 records · 2 shown of 2 Source Base de données publique des médic · Data as of 2026-11-03

US 1 records · 1 shown of 1 Source openFDA NDC Directory · Data as of 2026-10-23

  • 400 mg per mL / per unit basis not statedinjectionOrbactiv

GB 1 records · 1 shown of 1 Source NHSBSA dm+d · Data as of 2026-10-19

  • 400 mg per mL / per unit basis not statedinjectionTenkasi 400mg powder for concentrate for solution for infusion vials

EU 1 records · 0 shown of 0 Source European Commission · Data as of 2026-11-03 · some records have no stated strength

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名TENKASI ×2

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.